Lipodystrophy

Lipodystrophy features

• 

  Body fat changes in people with HIV: a clinical review

  This article reviews the antiretroviral side-effect of lipoatrophy (fat loss) in resource-limited settings....

  From:  HIV & AIDS treatment in practice

• 

  How frequently are ARV side-effects being seen in resource-limited settings, and how are they dealt with?

  Review of major side-effects of first-line antiretroviral regimens in resource-limited settings, and what can be done to reduce or avoid them....

  From:  HIV & AIDS treatment in practice

Lipodystrophy news from aidsmap

• High rate of infections in people with HIV receiving Bio-Alcamid treatment for facial lipoatrophy

  Bio-Alcamid treatment for HIV-related lipoatrophy is associated with a high-rate of infectious complications, Canadian investigators report in the online edition of Clinical Infectious Diseases. The infections typically developed years after initial therapy with Bio-Alcamid and dental work and facial manipulation were ...

  10 September 2012 | Michael Carter

• Reductions in visceral fat during tesamorelin therapy associated with improvements in key metabolic markers

  Reductions in visceral adiposity achieved with tesamorelin therapy are associated with improvements in some key metabolic parameters, according to a study published in the online edition of Clinical Infectious Diseases. The HIV-positive patients who responded to the therapy had ...

  30 April 2012 | Michael Carter

• Lipoatrophy common in children receiving d4T in South Africa

  Exposure to d4T (stavudine) among young children in sub-Saharan Africa remains the greatest risk factor for lipodystrophy syndrome (that includes lipoatrophy and lipohypertrophy) for a significant proportion of children, urgently highlighting the need for early detection of abnormal body fat ...

  07 March 2012 | Carole Leach-Lemens

• Fat accumulation linked to cognitive impairment in patients with HIV

  Central fat accumulation is associated with an increased risk of neurocognitive impairment for HIV-positive patients, according to a study published in the February edition of Neurology. Overall 40% of patients in the study were diagnosed with impairment and increased waist circumference ...

  24 February 2012 | Michael Carter

• Raltegravir kinder to bones and body fat than boosted protease inhibitors in Spanish trial

  Raltegravir (Isentress)-based treatment appears to have a more favourable impact on fat accumulation and bone metabolism compared to therapy based on a ritonavir-boosted protease inhibitor, according to Spanish research published in the online edition of AIDS. The study involved ...

  28 November 2011 | Michael Carter

• Diseases of ageing occurring 10 to 15 years earlier in patients with HIV

  The diseases of ageing develop earlier in patients with HIV than in the general population, Italian investigators report in the online edition of Clinical Infectious Diseases. “Our findings suggest that an aggressive approach to the screening, diagnosis, and treatment of ...

  20 October 2011 | Michael Carter

• Waist circumference and triglycerides: simple measures of increased cardiovascular risk for patients with HIV

  Measuring waist circumference and triglyceride levels may be an easy way of identifying which HIV-positive patients have an increased risk of cardiovascular disease, according to research published in PLoS One. Italian investigators found a consistent and significant relationship between ...

  10 October 2011 | Michael Carter

• Kivexa and Truvada-based combinations associated with long-term gains in limb fat, not fat loss

  Modern antiretroviral regimens based on Kivexa and Truvada are associated with long-term gains in limb fat, US investigators report in the July 15th edition of Clinical Infectious Diseases. After 96 weeks of therapy limb fat levels had increased by approximately ...

  27 June 2011 | Michael Carter

• Amount of fat around the heart can predict cardiovascular risk for patients with HIV

  Measuring the volume of fat around the heart can help predict which HIV-positive patients have an increased risk of cardiovascular disease, an Italian study published in the online edition of AIDS suggests. Investigators used CT scans to monitor ...

  27 April 2011 | Michael Carter

• Young adults who were infected at birth: the complexities of lifelong HIV are increasingly apparent

  Although 85% of young adults who take antiretroviral therapy have an undetectable viral load, the complexities and complications of lifelong HIV infection are becoming increasingly apparent, researchers told the British HIV Association conference in Bournemouth last week. Rates of hospital admissions, ...

  11 April 2011 | Roger Pebody

More news

Lipodystrophy news selected from other sources

• Health Canada rejects tesamorelin for lipodystrophy

  After consideration of the NDS, Health Canada decided that the risks of tesamorelin outweighed its benefits under the proposed conditions of use.

  13 March 2013 | Theratechnologies press release

• Mark S. King: I'm Gonna Wipe That AIDS Right Off My Face

  It was all well and good to be front and center as an HIV-positive man during the first years of the AIDS crisis. It's easier being a role model when your face looks good on the poster. But then, slowly but surely, a common side effect of HIV medications, facial wasting, began to appear.

  30 January 2013 | Huffington Post

• The Bio-Alcamid disaster

  “Nightmare.” That’s how one man described a weeks-long ordeal involving ad hoc surgery, repeated infections and some hefty out-of-pocket fees – all caused by a device that was once thought to be a miracle for those dealing with the visible signs of HIV.

  08 October 2012 | Xtra

• The mirror has two faces - a personal account of using facial filler for lipoatrophy

  In the end, for me the few small lumps, the cost of treatment, and the pain were all a small price to pay for what it has ultimately done for my self-esteem. I feel better about myself overall, because I look healthier.

  28 September 2012 | Positively Aware

• Theratechnologies sinks on HIV drug setback

  The Committee for Medicinal Products for Human Use in Europe cited potential concerns for long-term users and a lack of data on cardiovascular risks as the reason for its unfavorable view of the drug, Theratechnologies said in a statement.

  22 June 2012 | Reuters

• Why it's time to say goodbye to stavudine...everywhere

  Concerns about a proposed comparative trial of 40mg and 20mg (low-dose) stavudine in South Africa.

  16 April 2012 | South African Journal of HIV Medicine

• Face fillers and dental work—caution needed

  Reconstructive surgery to deal with the loss of subcutaneous fat in the face involved injection of facial fillers. One product used was polyalkylimide gel (PAIG, Bio-Alcamid). However, reports began to emerge from Western Europe of inflammation and infections in both HIV-negative and HIV-positive people with Bio-Alcamid implants. 

  25 January 2012 | CATIE

• Theratechnologies to discontinue COPD clinical program and focus on lipodystrophy

  The Company will now focus its efforts on tesamorelin's significant potential for the treatment of excess abdominal fat in HIV patients with lipodystrophy. Currently, applications for this indication are under review with regulatory agencies in Europe, Argentina, Brazil, Canada, Israel and Mexico.

  08 December 2011 | Theratechnologies press release

• Body Satisfaction Increased With Fat Gains in Prezista Study

  Although treatment experienced HIV-positive men and women had slightly greater gains in trunk fat after switching to a new regimen containing Prezista (darunavir), they also reported increased satisfaction with their bodies.

  17 June 2011 | AIDSMeds

• Theratechnologies seeks European marketing for lipodystrophy drug Tesamorelin

  Theratechnologies Inc. says it has applied to sell its lead drug tesamorelin in Europe. The drug is a treatment for excess abdominal fat in adult HIV-infected patients with lipodystrophy.

  07 June 2011 | Stock House

More news